Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.64 |
| ▸ | PPARG | P37231 | 10/20 | 0.59 |
| ▸ | PPARA | Q07869 | 10/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1586389 | 0.88 | FFAR1 (0.64) | FFAR1PPARGPPARAKDRMAPT | |
| SCHEMBL2520541 | 0.87 | FFAR1 (0.62) | FFAR1PPARGPPARAKDRMAPT | |
| SCHEMBL3984209 | 0.86 | PPARG (0.55) | FFAR1PPARGPPARAMAPTTP53 | |
| SCHEMBL4602181 | 0.84 | PPARG (0.56) | FFAR1PPARGPPARAMAPTTP53 | |
| SCHEMBL4030957 | 0.84 | FFAR1 (0.70) | FFAR1PPARGPPARAKDRMAPT | |
| Hydrochloric Acid SCHEMBL3984019 | 0.84 | PPARG (0.55) | FFAR1PPARGPPARAMAPTTP53 | |
| SCHEMBL19392906 | 0.82 | FFAR1 (0.68) | FFAR1PPARGPPARAKDRMAPT | |
| SCHEMBL4850515 | 0.82 | FFAR1 (0.71) | FFAR1PPARGPPARAKDRMAPT | |
| SCHEMBL4032011 | 0.81 | FFAR1 (0.70) | FFAR1PPARGPPARAKDRMAPT | |
| SCHEMBL6959523 | 0.81 | FFAR1 (0.70) | FFAR1PPARGPPARAKDRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251171-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BACH ANDREW THOMAS | 2011-10-13 | — | — | US | disclosed |
| CN-101362731-B | Heterocyclic compounds and methods of use | NOVARTIS AG | 2011-01-19 | — | — | CN | disclosed |
| US-20100152255-A1 | Organic Compounds | DAMON ROBERT EDSON | 2010-06-17 | — | — | US | disclosed |
| US-7700637-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20090118160-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BACH ANDREW THOMAS | 2009-05-07 | — | — | US | disclosed |
| CN-100482649-C | Organic compounds | NOVARTIS AG (CH) | 2009-04-29 | — | — | CN | disclosed |
| CN-101362731-A | Heterocyclic compounds and methods of use | NOVARTIS AG (CH) | 2009-02-11 | — | — | CN | disclosed |
| CN-100429201-C | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2008-10-29 | — | — | CN | disclosed |
| EP-1448523-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | NOVARTIS AG (CH) | 2007-08-22 | — | — | EP | disclosed |
| US-20070135502-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BACH ANDREW T | 2007-06-14 | — | — | US | disclosed |
| US-7183304-B2 | such as (R)-1-{4-[4-(4-Phenoxy-2-propyl-phenoxy)-butoxy]-benzenesulfonyl}-azetidine-2-carboxylic acid, used as peroxisome proliferator-activated receptor agonists; hypoglycemic agents | NOVARTIS AG (CH) | 2007-02-27 | — | — | US | disclosed |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | NOVARTIS AG (CH) | 2007-01-04 | — | — | US | disclosed |
| EP-1664002-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026134-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-03-24 | — | — | WO | disclosed |
| CN-1589260-A | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2005-03-02 | — | — | CN | disclosed |
| US-20040248936-A1 | Heterocyclic compounds and methods of use | BACH ANDREW THOMAS (US) | 2004-12-09 | — | — | US | disclosed |
| EP-1448523-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Novartis AG (CH) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003043985-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | NOVARTIS AG (CH) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118160-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PPARG, PPARA, PPARD | FFAR1 9/4885PPARG 1/4885PPARA 2/4885 |
| US-20040248936-A1 | Heterocyclic compounds and methods of use | PPARG, GPR119, PPARD | FFAR1 6/4885PPARG 1/4885PPARA 4/4885 |
| US-20100152255-A1 | Organic Compounds | PPARG, FABP2, PPARA | FFAR1 18/4885PPARG 1/4885PPARA 3/4885 |
| US-20110251171-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PPARG, PPARA, PPARD | FFAR1 9/4885PPARG 1/4885PPARA 2/4885 |
| US-20070135502-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PPARG, PPARA, PPARD | FFAR1 9/4885PPARG 1/4885PPARA 2/4885 |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | PPARG, GPR119, PPARA | FFAR1 11/4885PPARG 1/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.